


SYNTHESIS OF 2'(S), 3'(R), 5'-TRIHIDROXYPENTYLADENINE<sup>1</sup>

CHIA-LIN J. WANG\*, SIMON H. STAM<sup>2</sup>, AND JOSEPH M. SALVINO<sup>2</sup>

E. I. DU PONT DE NEMOURS AND COMPANY, INC., MEDICAL PRODUCTS DEPARTMENT  
PHARMACEUTICAL RESEARCH AND DEVELOPMENT DIVISION, EXPERIMENTAL STATION  
WILMINGTON, DE 19898


**ABSTRACT:** A synthesis of 2'(S), 3'(R), 5'-trihydroxypentyladenine (1) from D-ribonic acid  $\gamma$ -lactone (2) is described.


In a project directed towards the synthesis of enzyme inhibitors, we needed 2'(S), 3'(R), 5'-trihydroxypentyladenine (1). Surprisingly, literature showed that only 2'(R), 3'(S), 5'-trihydroxypentyladenine with the configurations at C-2' and C-3' opposite to those in D-ribose was known.<sup>3</sup> In view of the recent interest in synthesis of open-chain nucleoside and nucleotide analogs as biologically active agents,<sup>4</sup> we wish to report the synthesis of 1 having the same configurations at C-2' and C-3' as those of D-ribose from commercially available D-ribonic acid  $\gamma$ -lactone (2).



The strategy shown in Scheme 1 was to remove the oxygen functionality at C-4 in 2, and to convert C-1 of 2 after ring-opening into a mesylate ( $\text{CH}_2\text{OM}_s$ ) so that adenine could be attached.

Scheme 1





D-Ribonic acid  $\gamma$ -lactone was converted into its acetonide<sup>5</sup> and the primary hydroxy group was protected as benzyl ether to give compound **3**. The crude lactone **3** was reduced with lithium aluminum hydride in ether at 0°C to afford **4** as a white solid in ca 30% overall yield

from 2 after HPLC purification [mp 33°C;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 7.32 (s,5H), 4.57 (s,2H), 4.50-3.50 (m,7H), 3.20 (bs,2H,-OH), 1.33 (2s,6H)]. The primary hydroxy group in 4 was protected with *tert*-butyldiphenylsilyl chloride to yield silyl ether 5 in 98% yield [ $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 7.75-7.33 (m,15H), 4.64 (s,2H), 4.50-3.50 (m,7H), 1.33 (s,6H), 1.11 (s,9H)].

In order to remove the C-4 hydroxy group, we used Barton's procedure.<sup>6</sup> Thus, treatment of 5 with sodium hydride and carbon disulfide in the presence of imidazole followed by methyl iodide gave dithiocarbonate 6 in 87% yield after HPLC purification [ $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 7.75-7.15 (m,15H), 5.80 (m,1H), 4.60-3.50 (m,6H), 4.50 (s,2H), 2.43 (s,3H), 1.43 (s,3H), 1.37 (s,3H), 1.07 (s,9H)]. Compound 6 was then treated with tributyltin hydride in refluxing toluene to afford the C-4 deoxygenated product 7 which was contaminated with tin side-product even after purification by flash column chromatography. This side product, however, could be easily removed by extraction in next step. The silyl ether protecting group in 7 was removed by tetrabutylammonium fluoride in THF. The crude product was dissolved in acetonitrile and washed with hexane to get rid of the tin side-product from the previous reaction. Then purification by flash column chromatography gave pure product 8 as an oil in 46% yield from 6 [ $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 7.33 (s,5H), 4.52 (s,2H), 4.30-4.00 (m,2H), 3.60 (t,4H), 2.18 (t,1H,-OH), 1.86 (dt,2H), 1.43 (s,3H), 1.33 (s,3H)].

At this stage we were ready to attach the adenine molecule. Thus, the hydroxy group in 8 was converted into mesylate 9. Displacement of the mesylate in 9 with adenine anion gave only a low yield of the desired product. Therefore, the acetonide was removed with *p*-toluenesulfonic acid in methanol to afford the mesylate 10 which was directly reacted with adenine in DMF at 90°C in the presence of sodium hydride. Purification by flash column chromatography gave the desired N<sub>9</sub>-alkylation product 11 as a solid in 70% yield from 8 [mp 117-123°C;  $^1\text{H-NMR}$  ( $d_6$ -DMSO)  $\delta$ : 8.13 (s,1H), 8.01 (s,1H), 7.30 (m,5H), 7.22 (s,2H), 5.15 (d, J=6.6 Hz, 1H), 5.02 (d, J=6.6 Hz, 1H), 4.43 (s,2H), 4.40 (bs, 1H), 4.03 (dd,1H), 3.57 (t,3H), 3.43 (m,1H), 2.00 (m,1H), 1.55 (m,1H); MS:  $m/z$  344 ( $M^+ + 1$ );  $[\alpha]_D = -9.8^\circ$  ( $c=1$ , MeOH)]. A side-product was isolated in ca. 16% yield and it was assigned as N<sub>3</sub>-alkylation product 12. Structural assignments were based on the C-2, C-8 purine proton signal differences ( $\Delta\delta_{2,8}$ ), which were 0.12 ppm for 11 and 0.4 ppm for 12. In addition, the chemical shifts of N-CH<sub>2</sub> in 11 were at higher field compared with those of 12. These observations were consistent with the results reported in the literature.<sup>7</sup> Finally, removal of the benzyl group by Pd(OH)<sub>2</sub>/C in refluxing ethanol in the presence of cyclohexene gave 1 as a white solid in 45% yield from 11 [mp >200°C (dec);  $^1\text{H-NMR}$  ( $d_6$ -DMSO)  $\delta$ : 8.11 (s,1H), 8.03 (s,1H), 7.20 (s,2H), 5.17 (d, J=6.6 Hz, 1H), 4.95 (d, J=6.6 Hz, 1H), 4.39 (m,2H), 4.00 (dd,1H), 3.53 (m,3H), 3.37 (m,1H), 1.78 (m,1H), 1.43 (m,1H); HRMS:  $m/z$  253.1179 ( $M^+$ ), calcd for C<sub>10</sub>H<sub>15</sub>N<sub>5</sub>O<sub>3</sub>, 253.1175;  $[\alpha]_D = -3^\circ$  ( $c=0.1$ , DMF)].

In conclusion, we have synthesized 2'(S), 3'(R), 5'-trihydroxypentyladenine (1) with the same configurations at C-2' and C-3' as those of D-ribose from D-ribonic acid  $\gamma$ -lactone (2) in eleven steps in 4% overall yield.

Acknowledgements: We thank Dr. R. L. Magolda for suggesting use of 2 as a starting material. Special thanks go to Ms. T. L. Taylor for experimental assistance. We also thank Ms. P. Adcock for helping in the preparation of the manuscript.

#### REFERENCES AND NOTES

1. Contribution No. 87-P60 from Medical Products Department.
2. Central Research and Development Department.
3. S. N. Mikhailov, L. I. Kolobushkina, A. M. Kritzyn, and V. L. Florentiev, Tetrahedron, 32, 2409 (1976).
4. (a) K. Okumura et al., J. Med. Chem., 17, 846 (1974); (b) E. De Clercq, J. Descamps, P. De Somer, and A. Holy, Science, 200, 563 (1978); (c) A. Holy, I. Votruba, and E. De Clercq, Collec. Czech. Chem. Commun., 50, 245 (1984); (d) A. Holy, Bio-Organic Heterocycles 1986-Synthesis, Mechanisms and Bioactivity, Proceedings of the 4th FECEM Conference on Heterocycles in Bio-Organic Chemistry, Ed. by H. C. van der Plas et al., p. 91, 1986.
5. L. Hough, J. K. N. Jones, and D. L. Mitchell, Can. J. Chem., 36, 1720 (1958).
6. D. H. R. Barton and S. W. McCombie, J. Chem. Soc., Perkin Trans. 1, 1975, 1574.
7. A. E. Beasley and M. Rasmussen, Aust J. Chem., 34, 1107 (1981).

(Received in USA 20 November 1987)